Details for Patent: 8,394,826
Which drugs does patent 8,394,826 protect, and when does it expire?
Patent 8,394,826 protects RHOPRESSA and ROCKLATAN and is included in two NDAs.
This patent has thirty patent family members in eight countries.
Summary for Patent: 8,394,826
| Title: | Dual mechanism inhibitors for the treatment of disease |
| Abstract: | Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved. |
| Inventor(s): | Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty |
| Assignee: | Alcon Inc |
| Application Number: | US12/694,965 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,394,826 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,394,826
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | RHOPRESSA | netarsudil mesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE | ⤷ Start Trial | ||
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,394,826
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3053913 | ⤷ Start Trial | 301038 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3053913 | ⤷ Start Trial | 122020000016 | Germany | ⤷ Start Trial |
| European Patent Office | 3053913 | ⤷ Start Trial | 2020C/510 | Belgium | ⤷ Start Trial |
| European Patent Office | 3053913 | ⤷ Start Trial | 132020000000043 | Italy | ⤷ Start Trial |
| European Patent Office | 3053913 | ⤷ Start Trial | 2020/016 | Ireland | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
